Skip to main content
. Author manuscript; available in PMC: 2014 Feb 1.
Published in final edited form as: J Immunother. 2013 Feb;36(2):112–123. doi: 10.1097/CJI.0b013e3182811ce9

Figure 2. Redirected specificity of CAR+ T cells.

Figure 2

(a) The percentage of specific lysis by red-fluorescent-labeled CD19-specific CAR+ T cells for EGFP+CD19neg U251T parental glioma cells and EGFP+CD19+ U251T target cells. Upper panel: U251T parental targets; lower panel, U251T genetically modified targets. (b) Specific lysis of the target cells by CAR+ T cells. (c) Targets used for CRA. Expression of truncated CD19 in mouse NSO cells and primary human CD3+ T cells (autologous targets). Also shown is the expression of CAR on genetically modified T cells. (d) CAR+ T cells lyse both CD19+ NS0 cells and autologous CD19+ T cells, while sparing CD19neg NS0 and CD19negCAR+ autologous T cells, as measured by 4 hour CRA.